[Immunocheckpoint inhibition in head and neck squamous cell carcinoma: the current status and progress]

Area of Science:

• Oncology
• Immunology
• Head and Neck Cancer Research

Background:

• Advanced head and neck squamous cell carcinoma (HNSCC) treatment remains challenging, with limited improvement from current therapies like cetuximab and chemotherapy.
• The prognosis for HNSCC patients is generally poor, necessitating novel therapeutic strategies.
• Tumor immunological therapy has emerged as a promising field for cancer treatment.

Purpose of the Study:

• To systematically review the progress of immune checkpoint inhibitors (ICIs) in HNSCC treatment.
• To discuss the efficacy of combination therapies involving ICIs in HNSCC.
• To explore potential biomarkers related to immunotherapy efficacy in HNSCC.

Main Methods:

• Systematic literature review of clinical studies and research on immune checkpoint inhibitors in HNSCC.
• Analysis of data regarding the anti-tumor effects of ICIs, including programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors.
• Discussion of immunotherapy efficacy-related biomarkers in the context of HNSCC.

Main Results:

• Immune checkpoint inhibitors targeting PD-1/CTLA-4 have demonstrated anti-tumor effects in various cancers, including melanoma and non-small cell lung cancer.
• Early clinical studies indicate potential benefits of ICIs in HNSCC, suggesting a new avenue for improving patient outcomes.
• The review synthesizes current knowledge on ICI efficacy and combination strategies in HNSCC.

Conclusions:

• Immune checkpoint inhibitors represent a significant advancement in the potential treatment of head and neck squamous cell carcinoma.
• Combination therapies and biomarker identification are crucial for optimizing ICI efficacy in HNSCC.
• Further research and clinical trials are warranted to fully realize the potential of immunotherapy for improving HNSCC prognosis.